Net Cash Provided by (Used in) Financing Activities of REGENXBIO Inc. from 31 Dec 2016 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
REGENXBIO Inc. annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2016 to 31 Dec 2025.
  • REGENXBIO Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $5,794,000, a 105% decline year-over-year.
  • REGENXBIO Inc. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $116,771,000, a 26% increase from 2024.
  • REGENXBIO Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $92,683,000.
  • REGENXBIO Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $34,966,000, a 21% decline from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

REGENXBIO Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $116,771,000 +$24,088,000 +26% 01 Jan 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
2024 $92,683,000 +$127,649,000 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY
2023 $34,966,000 -$6,126,000 -21% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $28,840,000 -$224,090,000 -115% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2025 2024 FY
2021 $195,250,000 -$4,964,000 -2.5% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $200,214,000 +$191,838,000 +2290% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $8,376,000 -$196,067,000 -96% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $204,443,000 +$119,845,000 +142% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2021 2020 FY
2017 $84,598,000 +$84,479,000 +70991% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $119,000 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY

REGENXBIO Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $5,794,000 -$126,519,000 -105% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q1 2024 $120,725,000 +$129,762,000 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q1 2023 $9,037,000 -$2,203,000 -32% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q1 2022 $6,834,000 -$218,120,000 -103% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q1 2021 $211,286,000 +$208,525,000 +7553% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q1 2020 $2,761,000 -$1,366,000 -33% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q1 2019 $4,127,000 -$39,000 -0.94% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q1 2018 $4,166,000 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.